DSGN Design Therapeutics, Inc.
USHealthcareAs of 2026-07-09 10:27
Why DSGN matters now
Design Therapeutics, Inc. (DSGN) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.10 with -1.18% on the session and $943.1M in market capitalization; recent performance reads 1-month +18.59% and YTD +32.62%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-17.6M, and EPS of $-0.29. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -7.0%.
The latest indexable market news headline is "Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $20.50; recent insider activity includes Berger Heather A. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.50
P/S
0.00
EV/EBITDA
-11.10
DCF Value
$0.26
FCF Yield
-7.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-33.1%
ROA
-30.3%
ROIC
-35.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-17.6M | $-0.29 |
| Q4 2025 | $0.00 | $-16.0M | $-0.27 |
| FY 2025 | $0.00 | $-69.8M | $-1.22 |
| Q3 2025 | $0.00 | $-17.0M | $-0.30 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$20.50
Target (Median)
$20.50
Target Range
$20.00 - $21.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.66
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.